Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Olga O. Shakhmatova"'
Autor:
Olga O. Shakhmatova, Andrey L. Komarov, Elena N. Krivosheeva, Anatoly B. Dobrovolsky, Elena V. Titaeva, Vera A. Amelyushkina, Nataliya V. Gomyranova, Elizaveta P. Panchenko
Publikováno v:
Терапевтический архив, Vol 95, Iss 9, Pp 763-768 (2023)
Background. The role of albuminuria as a marker of the atherosclerosis burden and a predictor of prognosis in patients with polyvascular disease (PD) has been little studied. Aim. To evaluate the prevalence, association with atherosclerosis burden
Externí odkaz:
https://doaj.org/article/4b7168fe5ec34714a30e4f5f29c70ad8
Autor:
Olga O. Shakhmatova
Publikováno v:
Атеротромбоз, Vol 0, Iss 2, Pp 147-157 (2018)
Idaruzizumab (Praxbind©) is a specific reversal agent for dabigatran, which is a humanized Fab fragment of a monoclonal antibody. Immediately after administration, the drug binds to dabigatran and its metabolites, inhibiting 99% of the anti-coagulan
Externí odkaz:
https://doaj.org/article/7d845f72108d4650a7320cee240c5499
Autor:
Irina A Merkulova, Eric A Avetisyan, Olga O Shakhmatova, Vladimir I Ganyukov, Dmitry V Pevzner
Publikováno v:
Circulation. 144
Introduction: Left atrial appendage occlusion (LAAO) is non-inferior to warfarin and direct oral anticoagulants (DOAC) in thromboembolic prophylaxis in atrial fibrillation (AF). However, these antithrombotic strategies in patients with and without co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e24c7dc24f609361d96d3c68dcfb5f1
https://doi.org/10.1161/circ.144.suppl_1.11107
https://doi.org/10.1161/circ.144.suppl_1.11107